12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Belinostat: Phase II data

Top-line data from the open-label, international pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat met the primary endpoint of an ORR of >=20%. Topotarget said the data are being further analyzed and will be...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >